Abbott Laboratories All Financial Data in US $ (mln)

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2018) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile

Profile Abbott Laboratories (ABT) is an Illinois based diverse healthcare company focused on the development of diagnostics, medical devices, nutritional products & pharmaceuticals.

01 JAN 2013: Abbott spun-out "AbbVie" as a new research-based pharmaceutical company. Within EvaluatePharma®, pro-forma financials, opdata & product sales covered for AbbVie for years 2011 & 2012.
Listed or Private Company Listed
Company Classification Generic; MedTech
Country USA
Company Website Website
Technology Platform Profile
Full Company Profile Information

EventAnalyzer - Last Key Event

Closing Price DateClosing Price Date EventAnalyzer Note Market Cap (US $m) Change (%) Change (+$m)
17/07/2014 17 Jul: Company reports better-than-expected Q2'14 results on 16 Jul, driven by strong sales of its medical diagnostics products, and company raises its 2014 earnings guidance. Multiple analysts raise price targets. 62,931 2.1% 1,276

Top 3 Products (Worldwide Sales)

Annual Sales WW - Sales Growth per Year (%)
Rank1 ProductProduct Generic NameGeneric Name Therapeutic Subcategory 2012 2013 2013
1 Biaxin clarithromycin Anti-bacterials 501 416 -17%
2 Creon pancrelipase (amylase;lipase;protease) Other gastro-intestinal agents 306 323 +5%
3 TriCor fenofibrate Anti-hyperlipidaemics 2922 290 -1%
Note: Shaded Cells3

RX Sales Chart

Abbott Laboratories Data Growth
2012 2013 2013
 Revenues By Segment
     Pharmaceuticals Sales (In-depth)
       Rx & OTC Pharmaceuticals
         Prescription (Rx) Pharmaceuticals 5,1214 4,9745 -3%

Therapy Area Focus

Abbott Laboratories
 WW Rx & OTC Sales By Therapy Area
  Main Categories
     Blood 84
     Cardiovascular 736
     Central Nervous System 448
     Endocrine 175
     Gastro-Intestinal 607
     Genito-Urinary 355
     Systemic Anti-Infectives 646
     Other Rx & OTC Pharma 1,924

EvaluatePharma® Coverage of Marketed and Pipeline Products

Product Count
Abbott Laboratories 6 768


Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.

EP Vantage - last 6 months
HeartWare falls further behind with next-gen device pause (October 14, 2015)
Absorb data could allow Abbott to retain stent leadership (October 13, 2015)
Boston arrives late to the mitral valve party (October 09, 2015)
Interview – Edwards looks to tricuspid valves and beyond (October 08, 2015)
Reanimated $2bn Steris-Synergy merger could presage more deals (September 25, 2015)

Displaying 5 out of a possible 18 unique stories.
Results Sorted By date

Register to access more FREE content:

  • 2011 Product Sales analysis
  • 2011 Pharmaceutical Sales
  • 2011 Market Share & Global Ranking
  • Download to Excel
  • Search 2 yrs of company press releases

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now